


ADVANCING

what's possible



ADC Therapeutics is advancing
what's possible in cancer therapy.



THERAPEUTICS
Innovating Science. Inspiring Hope.

adctherapeutics.com

ADC Therapeutics

Confronting cancer with the full potential of our science.

ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation ADCs for those affected by cancer. We are pioneers in ADC technology and have a deep understanding of the oncology treatment landscape, and we intend to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

our mission We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

our vision We will transform what patients and their families can expect from cancer therapy.

Our team at ADCT is purpose-driven. We are committed to making a positive impact on patients' lives with our innovative ADC products. We have over a decade of experience in the field of ADCs and we are expanding our technology toolbox to ensure we harness the full potential of ADCs to address the unmet medical needs of patients with cancer.

Ameet Mallik

Chief Executive Officer, ADC Therapeutics



Our History

- June 2011** ADC Therapeutics founded as a spinoff from Spirogen Ltd, an early innovator in PBD-based ADC research
- March 2016** 1st patient enrolled in Phase 1 clinical trial of lead investigational compound targeting CD-19 (loncastuximab tesirine-lpyl) in positive B-Cell non-Hodgkin lymphoma
- August 2018** 1st patient dosed in pivotal Phase 2 trial with loncastuximab tesirine-lpyl
- October 2019** 1st patient enrolled in Phase 2 clinical trial of CD-25 targeted investigational compound in relapsed or refractory Hodgkin lymphoma
- May 2020** ADC Therapeutics joins the NYSE as ticker ADCT
- Nov 2020** FDA accepts BLA and grants priority review for loncastuximab tesirine-lpyl for CD-19 directed therapy
- Dec 2020** ADC Therapeutics and Overland Pharmaceuticals form Overland ADCT BioPharma to develop and commercialize ADCT products, including loncastuximab tesirine-lpyl, in greater China and Singapore
- April 2021** CD-19 targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
- September 2021** BLA submission for loncastuximab tesirine-lpyl
- January 2022** ADCT announces exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of loncastuximab tesirine-lpyl for all hematologic and solid tumor indications in Japan
- August 2022** ADCT announces exclusive licensing agreement with Sobi to develop and commercialize loncastuximab tesirine-lpyl in Europe and select international territories
- September 2022** Loncastuximab tesirine-lpyl receives positive CHMP opinion in Europe for the treatment of relapsed or refractory diffuse large B-cell lymphoma



antibody drug conjugate (ADC)
biologics license application (BLA)
pyrrolobenzodiazepine (PBD)

adctherapeutics.com


ADVANCING

innovation



One of the ways we are delivering on the promise of science –
advancing next-generation PBD-based ADCs.

Our proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.



References

1. Kaplon H, et al. *mAbs*. 2020;12:e1703531.
2. Zammarchi F, et al. *Blood*. 2018;131:1094–1105.
3. Hartley JA, et al. *Sci Rep*. 2018;8:10479.

ADVANCING

*what's possible
innovation
clinical trials
scientific knowledge*



Scan the QR code to view
the ADC Therapeutics pipeline
or visit adctherapeutics.com

For general inquiries, please contact
info@adctherapeutics.com.

For more information about our clinical trials
and research, please contact
medicalinformation@ADCTherapeutics.com.
or call 1.855.690.0340



ADCTherapeutics.com

Stay informed



ADC Therapeutics Head Office | Route de la Corniche 3B, 1066 Epalinges, Switzerland
ADC Therapeutics America | 430 Mountain Avenue, Suite #404. New Providence, NJ 07974, USA
©2022 ADC Therapeutics SA. US-CORP-NPS-00038. All rights reserved.